课题基金 / 基金详情

Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia

Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
较低剂量（3-2-1 策略）与全剂量依鲁替尼治疗慢性淋巴细胞白血病的随机 3 期评估
批准号：
437565
负责人：
Hay Annette
金额：
$7.29万
依托单位：
Queen's University (Kingston, Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2020
资助国家：
加拿大
项目状态：
已结题
起止时间：
2020-10-01 至 2021-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=437565&lang=en
关键词：
Chronic Lymphocytic Leukemia De-Escalation Non-Inferiority Randomized Controlled Trial Toxicity

项目摘要

项目成果

Hay Annette的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Chronic lymphocytic leukemia (CLL) is an incurable blood malignancy with a long natural history, typically characterized by multiple recurrences and repeated requirement for treatment. Ibrutinib (Imbruvica®) has emerged as an effective novel therapy for t
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Phase III Non-Inferiority Randomized Controlled Trial (RCT) of Fixed-Duration Daratumumab Versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma
The TACtful Trial: A first-in-human multi-centre trial of BCMA specific T-cell antigen coupler infusion, generated from cryopreserved G-CSF-mobilized peripheral blood, in patients with relapsed and refractory multiple myeloma.
Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
Canadian Cell Therapies Workshop 2019
海外基金